<DOC>
	<DOC>NCT01557452</DOC>
	<brief_summary>Givinostat is expected to exert a clinically relevant therapeutic effect on polyarticular JIA through the inhibition of the production/release of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNFα, which are involved in the pathogenesis of the arthritic process.</brief_summary>
	<brief_title>An Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis (JIA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<criteria>subjects who had successfully completed the previous Dose Finding Study and were fully compliant to the inclusion/exclusion criteria described in the previous DSC/08/2357/36 patients with fever related to JIA or other systemic features of JIA during 12 months before entering the study active bacterial or mycotic infection requiring antimicrobial treatment episode of macrophage activation syndrome over the last 6 months baseline prolongation of QT/QTc interval, use of concomitant medications that prolong the QT/QTc interval or history of additional risk factors for TdP. clinically significant cardiovascular disease clinically significant illness i.e. any condition that in the opinion of the Investigator places the patient to unacceptable risk for adverse outcome if he/she were to participate in the study psychiatric illness/social situation that would limit compliance with study medication and protocol requirements inherited metabolic diseases presence of malignancy pregnancy or lactation positive blood test for HIV active EBV infection, active B and/or C hepatitis platelet count &lt;100x10(9)/L</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>JIA</keyword>
</DOC>